ArticleCurrent genetics2025
Effect of intraperitoneal cannabidiol (CBD) injection on intestine microbiome profile in a mouse model.
Article in Current genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cannabidiol (CBD) as an active ingredient is widely used in cosmetics, food, medical products, and dietary supplements. Recent studies suggest that CBD consumption may influence the gut microbiome, impacting overall health. The mechanism of CBD action on the intestinal microbiome may be linked to the endocannabinoid system, which plays a role in the normalization of the functions of the immune system. Additionally, CBD may have a direct influence on the gut by interacting with the intestinal microflora, regulating intestinal permeability, modulating immune responses, and affecting the gut-brain axis communication through the vagal signaling pathway. A study was conducted to analyze how different doses of CBD injected intraperitoneal could alter the microbial composition of the duodenum contents in a mouse model. Obtained results suggest that the impact of CBD on the intestine microbiome may be dosage-dependent. Statistical analysis revealed significant differences compared to the control group in the 0.2 mg/kg CBD and 20 mg/kg CBD dose groups for the genera Campilobacteriota, Firmicutes, Proteobacteria, and, specifically in the 0.2 mg CBD group, Cyanobacteria. In contrast, the 10 mg CBD dose group showed no statistically significant differences relative to the control. The Firmicutes phylum had the highest relative abundance in all groups, wherein its share was lower in the CBD-treated groups than in the control group. Lachnospiraceae_NK4A136_group, Muribaculaceae, and Akkermansia were predominant, with Lachnospiraceae_NK4A136_group decreasing and Akkermansia increasing in relative abundance in CBD-treated groups. Of the genera that showed statistically significant differences between groups, most belonged to the phylum Firmicutes, including the dominant Lachnospiraceae_NK4A136_group. These findings suggest that intraperitoneal CBD administration induces alterations in the duodenal microbiome, particularly affecting the Lachnospiraceae_NK4A136_group and the Akkermansia genera.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.